Pahwa R, Lyons K, Hubble J P, Busenbark K, Rienerth J D, Pahwa A, Koller W C
Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.
Mov Disord. 1998 May;13(3):465-7. doi: 10.1002/mds.870130315.
Gabapentin has been reported to be effective for essential tremor (ET) based on open-label trials. We studied gabapentin (1800 mg/day) and placebo in a double-blind crossover design in 20 ET patients. Eighteen patients completed the study and two patients dropped out as a result of adverse effects which resolved when the medication was discontinued. Tremor was assessed at baseline and after 2 weeks of gabapentin and placebo treatment. One patient was mildly improved and another was moderately improved with placebo. Similarly, one patient reported mild improvement and another patient had marked improvement with gabapentin. All the remaining patients either reported no change or were worse with both treatment arms. There was no significant difference for total tremor score, hand tremor score, handwriting scores, or pouring scores. Sickness Impact Profile scores were no different between placebo and gabapentin. Our results suggest that as an adjuvant therapy in ET, gabapentin has limited benefit.
基于开放标签试验，已有报道称加巴喷丁对特发性震颤（ET）有效。我们采用双盲交叉设计，对20例ET患者使用加巴喷丁（1800毫克/天）和安慰剂进行了研究。18例患者完成了研究，2例患者因不良反应退出研究，停药后不良反应消失。在基线时以及加巴喷丁和安慰剂治疗2周后对震颤进行了评估。1例患者使用安慰剂后有轻度改善，另1例有中度改善。同样，1例患者使用加巴喷丁后报告有轻度改善，另1例有显著改善。其余所有患者在两个治疗组中均报告无变化或病情恶化。总震颤评分、手部震颤评分、书写评分或倒水评分均无显著差异。安慰剂组和加巴喷丁组的疾病影响概况评分也无差异。我们的结果表明，作为ET的辅助治疗，加巴喷丁的益处有限。
